Xin Lang Cai Jing·2025-12-08 05:10Group 1 - The core business of Junshi Biosciences includes the research and commercialization of monoclonal antibody drugs, with 90.67% of revenue coming from drug sales, 8.74% from technology licensing, and 0.59% from technical services and others [2] - As of September 30, 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, representing a year-on-year growth of 42.06%, while the net profit attributable to shareholders was -596 million yuan, an increase of 35.72% year-on-year [2] - The number of shareholders increased by 15.17% to 35,900 as of September 30, 2025, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2] Group 2 - On December 5, Junshi Biosciences' stock rose by 0.70%, with a trading volume of 155 million yuan [1] - The financing buy-in amount on December 5 was 11.01 million yuan, while the financing repayment was 14.72 million yuan, resulting in a net financing outflow of -3.70 million yuan [1] - The total balance of margin trading for Junshi Biosciences reached 1.363 billion yuan, with the financing balance accounting for 4.89% of the circulating market value, indicating a high level compared to the past year [1]